A 58-year-old woman with COPD (GOLD stage 3, FEV₁ 30–49% predicted) and 2 moderate exacerbations in the past 12 months is started on maintenance therapy. Which combination regimen is the preferred first-line treatment?

Question

Accepted Answer

D. LAMA + LABA + ICS (triple therapy). ## First-Line Management of Moderate–Severe COPD with Exacerbation History

**Key Point:** Patients with COPD GOLD stage 3–4 AND a history of exacerbations (≥2 in past year) require triple therapy (LABA + LAMA + ICS) to reduce exacerbation frequency, hospitalization, and mortality.

**High-Yield:** GOLD 2023 Exacerbation-Based Strategy:
- **0 exacerbations:** LABA or LAMA monotherapy
- **≥1 exacerbation (moderate–severe disease):** LABA + ICS OR LAMA + LABA (dual therapy)
- **≥2 exacerbations OR ≥1 severe exacerbation:** LABA + LAMA + ICS (triple therapy) — **preferred**

## Triple Therapy Rationale

```mermaid
flowchart TD
  A[COPD patient with exacerbation history]:::outcome --> B{Number of exacerbations?}:::decision
  B -->|0 exacerbations| C[LABA or LAMA monotherapy]:::action
  B -->|1 moderate exacerbation| D[LABA + ICS or LAMA + LABA]:::action
  B -->|≥2 exacerbations or 1 severe| E[LABA + LAMA + ICS Triple Therapy]:::action
  E --> F[Reduces exacerbations by 25-40%]:::outcome
  E --> G[Improves FEV₁ and quality of life]:::outcome
```

## Component Roles in Triple Therapy

| Component | Mechanism | Benefit in Exacerbations |
|---|---|---|
| **LAMA** | M3 antagonist | Reduces mucus hypersecretion; superior exacerbation reduction |
| **LABA** | β₂ agonist | Bronchodilation; synergistic with LAMA |
| **ICS** | Anti-inflammatory | Reduces airway inflammation; prevents exacerbation triggers |

**Clinical Pearl:** Triple therapy is the only regimen shown in RCTs (e.g., TRILOGY, TRINITY) to reduce exacerbation-related mortality in COPD. The combination is more effective than any dual therapy.

**Warning:** Oral corticosteroids are NOT first-line maintenance therapy — they are reserved for acute exacerbation management and carry long-term toxicity (osteoporosis, infection, hyperglycemia).

[cite:GOLD 2023 Report, Harrison 21e Ch 254]

Answer

A. LABA + ICS

Answer

B. Oral corticosteroid + LABA

Answer

C. LAMA monotherapy

A 58-year-old woman with COPD (GOLD stage 3, FEV₁ 30–49% predicted) and 2 moderate exacerbations in the past 12 months is started on maintenance therapy. Which combination regimen is the preferred first-line treatment?

Explanation

First-Line Management of Moderate–Severe COPD with Exacerbation History

Triple Therapy Rationale

Component Roles in Triple Therapy

Practice similar questions

Join our NEET PG community

Component	Mechanism	Benefit in Exacerbations
LAMA	M3 antagonist	Reduces mucus hypersecretion; superior exacerbation reduction
LABA	β₂ agonist	Bronchodilation; synergistic with LAMA
ICS	Anti-inflammatory	Reduces airway inflammation; prevents exacerbation triggers